Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL', Published online: 13 February 2018; doi:10.1038/nrclinonc.2018.19Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL' (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 13, 2018 Category: Cancer & Oncology Authors: David T. Teachey Michael R. Bishop David G. Maloney Stephan A. Grupp Source Type: research
Breast cancer: Recurrent fusions in endocrine-resistant disease
Breast cancer: Recurrent fusions in endocrine-resistant disease, Published online: 06 February 2018; doi:10.1038/nrclinonc.2018.26Breast cancer: Recurrent fusions in endocrine-resistant disease (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 6, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Haematological cancer: Blinatumomab facilitates complete responses
Haematological cancer: Blinatumomab facilitates complete responses, Published online: 06 February 2018; doi:10.1038/nrclinonc.2018.24Haematological cancer: Blinatumomab facilitates complete responses (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 6, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Immunotherapy: Local chemotherapy synergizes with CTLA-4 inhibition
Immunotherapy: Local chemotherapy synergizes with CTLA-4 inhibition, Published online: 06 February 2018; doi:10.1038/nrclinonc.2018.22Immunotherapy: Local chemotherapy synergizes with CTLA-4 inhibition (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 6, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Bridging the gap: are animal models consistent with clinical cancer cachexia?
Bridging the gap: are animal models consistent with clinical cancer cachexia?, Published online: 06 February 2018; doi:10.1038/nrclinonc.2018.14Experimental research on cancer-associated cachexia is advancing at an accelerated pace while knowledge of the complex underlying biology of cachexia in humans lags behind. An unmet need exists to accelerate the identification of causal mechanisms in patients with cancer and to determine the parallels between experimental systems and distinct isotypes of human cachexia. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 6, 2018 Category: Cancer & Oncology Authors: Vickie E. Baracos Source Type: research
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Targeting the IL-6/JAK/STAT3 signalling axis in cancer, Published online: 06 February 2018; doi:10.1038/nrclinonc.2018.8The interleukin-6 (IL-6)/Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) pathway is aberrantly hyperactivated in many types of cancer, and such hyperactivation is generally associated with a poor clinical prognosis. In this Review, the authors describe the clinical potential of agents designed to inhibit the IL-6/JAK/STAT3 signalling pathway, either alone or in combination with other agents, in patients with cancer. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 6, 2018 Category: Cancer & Oncology Authors: Daniel E. Johnson Rachel A. O ' Keefe Jennifer R. Grandis Source Type: research
Haematological cancer: Dasatinib regulates immune cell function
Haematological cancer: Dasatinib regulates immune cell function, Published online: 06 February 2018; doi:10.1038/nrclinonc.2018.25Haematological cancer: Dasatinib regulates immune cell function (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 6, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Melanoma: Neo/adjuvant BRAF/MEKi improves outcomes
Melanoma: Neo/adjuvant BRAF/MEKi improves outcomes, Published online: 06 February 2018; doi:10.1038/nrclinonc.2018.23Melanoma: Neo/adjuvant BRAF/MEKi improves outcomes (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 6, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Diagnosis: CancerSEEK and destroy — a blood test for early cancer detection
Diagnosis: CancerSEEK and destroy — a blood test for early cancer detection, Published online: 06 February 2018; doi:10.1038/nrclinonc.2018.21Diagnosis: CancerSEEK and destroy — a blood test for early cancer detection (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 6, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research
Approvals in 2017: gene therapies and site-agnostic indications
Approvals in 2017: gene therapies and site-agnostic indications, Published online: 31 January 2018; doi:10.1038/nrclinonc.2018.11In 2017, FDA Oncology approved 17 new drug and biologic applications, 32 supplemental drug and biologic applications, and two biosimilar applications in oncology. These actions included landmark approvals of two chimeric antigen receptor T cell therapies and the first site-agnostic, biomarker-defined approval. Three next-generation sequencing 'oncopanels' designed to detect hundreds of somatic genetic aberrations were also approved. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 31, 2018 Category: Cancer & Oncology Authors: Gideon M. Blumenthal Richard Pazdur Source Type: research
Paediatrics: Addressing the health burden of childhood cancer survivors — improvements are needed
Paediatrics: Addressing the health burden of childhood cancer survivors — improvements are needed, Published online: 31 January 2018; doi:10.1038/nrclinonc.2017.187Recently published data from a large-cohort study confirm the substantial burden of chronic health conditions among childhood cancer survivors, and describe the multiple chronic conditions faced by these individuals. The findings emphasize the need for specialized care in this unique patient population that, as discussed herein, often goes unmet. More must be done to ease the burden on cancer survivors; new models of care are required to improve their long-ter...
Source: Nature Clinical Practice Oncology - January 31, 2018 Category: Cancer & Oncology Authors: Tara O. Henderson Kevin C. Oeffinger Source Type: research
Haematological cancer: TGFβ-insensitive T cells provide sustained remissions in HL
Haematological cancer: TGFβ-insensitive T cells provide sustained remissions in HL, Published online: 31 January 2018; doi:10.1038/nrclinonc.2018.18Haematological cancer: TGFβ-insensitive T cells provide sustained remissions in HL (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 31, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Immunotherapy: Desmoplasia is no barrier to PD-1 blockade in melanoma
Immunotherapy: Desmoplasia is no barrier to PD-1 blockade in melanoma, Published online: 31 January 2018; doi:10.1038/nrclinonc.2018.16Immunotherapy: Desmoplasia is no barrier to PD-1 blockade in melanoma (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 31, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research
Immunotherapy: Targeting MDSCs with LXR agonists
Immunotherapy: Targeting MDSCs with LXR agonists, Published online: 31 January 2018; doi:10.1038/nrclinonc.2018.17Immunotherapy: Targeting MDSCs with LXR agonists (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 31, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research
Immunotherapy: Oncolytic viruses prime antitumour immunity
Immunotherapy: Oncolytic viruses prime antitumour immunity, Published online: 31 January 2018; doi:10.1038/nrclinonc.2018.15Immunotherapy: Oncolytic viruses prime antitumour immunity (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 31, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
